Viral hijacking of cellular ubiquitination pathways as an anti-innate immunity strategy

Viral Immunology

Volumn 19, Issue 3, 2006, Pages 349-362

  Chen, Mingzhou ^a,b   Gerlier, Denis ^a,c  

^a UNIVERSITÉ DE LYON   (France)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; VIRUS PROTEIN;

ADENOVIRUS; ANTIVIRAL ACTIVITY; CATALYSIS; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME SUBSTRATE; ENZYME SUBUNIT; GENE STRUCTURE; HERPES VIRUS; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; INNATE IMMUNITY; KAPOSI SARCOMA; LENTIVIRINAE; NONHUMAN; PARAMYXOVIRUS; RNA VIRUS; UBIQUITINATION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INFECTION; WART VIRUS; ZINC FINGER MOTIF;

EID: 33750959438     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.349     Document Type: Conference Paper

References (130)

1. Doherty PC and Turner SJ: The virus-immunity ecosystem. Arch Virol Suppl 2005;19:17-32.
2. Finlay BB and McFadden G: Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens. Cell 2006;124:767-782.
3. Iannello A, Debbeche O, Martin E, Attalah LH, Samarani S, and Ahmad A: Viral strategies for evading antiviral cellular immune responses of the host. J Leukoc Biol 2006;79:16-35.
4. Hemelaar J, Borodovsky A, Kessler BM, Reverter D, Cook J, Kolli N, Gan-Erdene T, Wilkinson KD, Gill G, Lima CD, Ploegh HL, and Ovaa H: Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol 2004;24:84-95.
5. Wilkinson KD: Ubiquitination and deubiquitination: Targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 2000;11:141-148.
6. Finley D, Ciechanover A, and Varshavsky A: Ubiquitin as a central cellular regulator. Cell 2004;116:S29-S32, 2 p following S32.
7. Hershko A and Ciechanover A: The ubiquitin system. Annu Rev Biochem 1998;67:425-479.
8. Banks L, Pim D, and Thomas M: Viruses and the 26S proteasome: Hacking into destruction. Trends Biochem Sci 2003;28:452-459.
9. Ciechanover A and Ben-Saadon R: N-terminal ubiquitination: More protein substrates join in. Trends Cell Biol 2004;14:103-106.
10. Ingham RJ, Gish G, and Pawson T: The Nedd4 family of E3 ubiquitin ligases: Functional diversity within a common modular architecture. Oncogene 2004;23:1972-1984.
11. Scheel H and Hofmann K: No evidence for PHD fingers as ubiquitin ligases. Trends Cell Biol 2003;13:285-287; author reply 287-288.
12. Hatakeyama S and Nakayama KI: U-box proteins as a new family of ubiquitin ligases. Biochem Biophys Res Commun 2003;302:635-645.
13. Ang XL and Wade Harper J: SCF-mediated protein degradation and cell cycle control. Oncogene 2005;24:2860-2870.
14. Castro A, Bernis C, Vigneron S, Labbe JC, and Lorca T: The anaphase-promoting complex: A key factor in the regulation of cell cycle. Oncogene 2005;24:314-325.
15. Liu YC: Ubiquitin ligases and the immune response. Annu Rev Immunol 2004;22:81-127.
16. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F, and Miller G: A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA 1998;95:10866-10871.
17. Yu Y, Wang SE, and Hayward GS: The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 2005;22:59-70.
18. Perry AK, Chen G, Zheng D, Tang H, and Cheng G: The host type I interferon response to viral and bacterial infections. Cell Res 2005;15:407-422.
19. Coscoy L, Sanchez DJ, and Ganem D: A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J Cell Biol 2001;155:1265-1273.
20. Dyson N, Howley PM, Munger K, and Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-937.
21. Scheffner M and Whitaker NJ: Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003;13:59-67.
22. Werness BA, Levine AJ, and Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-79.
23. Li TT, Zhao LN, Liu ZG, Han Y, and Fan DM: Regulation of apoptosis by the papillomavirus E6 oncogene. World J Gastroenterol 2005;11:931-937.
24. Crook T, Fisher C, Masterson PJ, and Vousden KH: Modulation of transcriptional regulatory properties of p53 by HPV E6. Oncogene 1994;9:1225-1230.
25. Gage JR, Meyers C, and Wettstein FO: The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J Virol 1990;64:723-730.
26. Sang BC and Barbosa MS: Single amino acid substitutions in "low-risk" human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the "high-risk" HPV E7 oncoproteins. Proc Natl Acad Sci USA 1992;89:8063-8067.
27. Huibregtse JM, Scheffner M, and Howley PM: Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993;13:775-784.
28. Talis AL, Huibregtse JM, and Howley PM: The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 1998;273:6439-6445.
29. Huibregtse JM, Scheffner M, and Howley PM: Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol Cell Biol 1993;13:4918-4927.
30. Gu J, Rubin RM, and Yuan ZM: A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation. Oncogene 2001;20:3519-3527.
31. Pim D, Storey A, Thomas M, Massimi P, and Banks L: Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene 1994;9:1869-1876.
32. Camus S, Higgins M, Lane DP, and Lain S: Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. FEBS Lett 2003;536:220-224.
33. Fehrmann F and Laimins LA: Human papillomaviruses: Targeting differentiating epithelial cells for malignant transformation. Oncogene 2003;22:5201-5207.
34. Kao WH, Beaudenon SL, Talis AL, Huibregtse JM, and Howley PM: Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J Virol 2000;74:6408-6417.
35. Favre-Bonvin A, Reynaud C, Kretz-Remy C, and Jalinot P: Human papillomavirus type 18 E6 protein binds the cellular PDZ protein TIP-2/GIPC, which is involved in transforming growth factor β signaling and triggers its degradation by the proteasome. J Virol 2005;79:4229-4237.
36. Liu X, Yuan H, Fu B, Disbrow GL, Apolinario T, Tomaic V, Kelley ML, Baker CC, Huibregtse J, and Schlegel R: The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J Biol Chem 2005;280:10807-10816.
37. Gross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C, and Ciechanover A: Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci USA 1998;95:8058-8063.
38. Veldman T, Liu X, Yuan H, and Schlegel R: Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci USA 2003;100:8211-8216.
39. Chen JJ, Reid CE, Band V, and Androphy EJ: Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 1995;269:529-531.
40. Patel D, Huang SM, Baglia LA, and McCance DJ: The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999;18:5061-5072.
41. Zimmermann H, Koh CH, Degenkolbe R, O'Connor MJ, Muller A, Steger G, Chen JJ, Lui Y, Androphy E, and Bernard HU: Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to down-regulate CBP/p300-mediated transactivation by p53. J Gen Virol 2000;81:2617-2623.
42. Li S, Labrecque S, Gauzzi MC, Cuddihy AR, Wong AH, Pellegrini S, Matlashewski GJ, and Koromilas AE: The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-α. Oncogene 1999;18:5727-5737.
43. Gupta S, Takhar PP, Degenkolbe R, Koh CH, Zimmermann H, Yang CM, Guan Sim K, Hsu SI, and Bernard HU: The human papillomavirus type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1. Virology 2003;317:155-164.
44. Ronco LV, Karpova AY, Vidal M, and Howley PM: Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-2072.
45. Oh KJ, Kalinina A, Wang J, Nakayama K, Nakayama KI, and Bagchi S: The papillomavirus E7 oncoprotein is ubiquitinated by UbcH7 and Cullin 1- and Skp2-containing E3 ligase. J Virol 2004;78:5338-5346.
46. Koromilas AE, Li S, and Matlashewski G: Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev 2001;12:157-170.
47. Barnard P and McMillan NA: The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α. Virology 1999;259:305-313.
48. Barnard P, Payne E, and McMillan NA: The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-α. Virology 2000;277:411-419.
49. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, and Woodworm CD: Papillomavirus type 16 oncogenes downregulate expression of interferon- responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J Virol 2001;75:4283-4296.
50. Porta C, Hadj-Slimane R, Nejmeddine M, Pampin M, Tovey MG, Espert L, Alvarez S, and Chelbi-Alix MK: Interferons α and γ induce p53-dependent and p53-independent apoptosis, respectively. Oncogene 2005;24:605-615.
51. Hagglund R and Roizman B: Role of ICPO in the strategy of conquest of the host cell by herpes simplex virus 1. J Virol 2004;78:2169-2178.
52. Van Sant C, Hagglund R, Lopez P, and Roizman B: The infected cell protein 0 of herpes simplex virus 1 dynamically interacts with proteasomes, binds and activates the cdc34 E2 ubiquitin-conjugating enzyme, and possesses in vitro E3 ubiquitin ligase activity. Proc Natl Acad Sci USA 2001;98:8815-8820.
53. Hagglund R, Van Sant C, Lopez P, and Roizman B: Herpes simplex virus 1-infected cell protein 0 contains two E3 ubiquitin ligase sites specific for different E2 ubiquitin-conjugating enzymes. Proc Natl Acad Sci USA 2002;99:631-636.
54. Boutell C, Sadis S, and Everett RD: Herpes simplex virus type 1 immediate-early protein ICPO and its isolated RING finger domain act as ubiquitin E3 ligases in vitro. J Virol 2002;76:841-850.
55. Everett RD, Meredith M, Orr A, Cross A, Kathoria M, and Parkinson J: A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J 1997;16:1519-1530.
56. Canning M, Boutell C, Parkinson J, and Everett RD: A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7. J Biol Chem 2004;279:38160- 38168.
57. Li M, Brooks CL, Kon N, and Gu W: A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004;13:879-886.
58. Boutell C, Canning M, Orr A, and Everett RD: Reciprocal activities between herpes simplex virus type 1 regulatory protein ICPO, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7. J Virol 2005;79:12342-12354.
59. Boutell C and Everett RD: The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and ubiquitinates p53. J Biol Chem 2003;278:36596-36602.
60. Parkinson J, Lees-Miller SP, and Everett RD: Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J Virol 1999;73:650-657.
61. Everett RD, Earnshaw WC, Findlay J, and Lomonte P: Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110. EMBO J 1999;18:1526-1538.
62. Lomonte P, Sullivan KF, and Everett RD: Degradation of nucleosome-associated centromeric histone H3-like protein CENP-A induced by herpes simplex virus type 1 protein ICP0. J Biol Chem 2001;276:5829-5835.
63. Boutell C, Orr A, and Everett RD: PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. J Virol 2003;77:8686-8694.
64. Chelbi-Alix MK and de The H: Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 1999;18:935-941.
65. Parkinson J and Everett RD: Alphaherpesvirus proteins related to herpes simplex virus type 1 ICPO affect cellular structures and proteins. J Virol 2000;74:10006-10017.
66. Gu H and Roizman B: The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a. Proc Natl Acad Sci USA 2003;100:8963-8968.
67. Craig KL and Tyers M: The F-box: A new motif for ubiquitin dependent proteolysis in cell cycle regulation and signal transduction. Prog Biophys Mol Biol 1999;72:299-328.
68. Hobbs WE, Brough DE, Kovesdi I, and DeLuca NA: Efficient activation of viral genomes by levels of herpes simplex virus ICPO insufficient to affect cellular gene expression or cell survival. J Virol 2001;75:3391-3403.
69. 1 into S phase of the cell cycle. J Virol 1999;73:9456-9467.
70. Everett RD: Herpes simplex virus type 1 regulatory protein ICPO does not protect cyclins D1 and D3 from degradation during infection. J Virol 2004;78:9599-9604.
71. Eidson KM, Hobbs WE, Manning BJ, Carlson P, and DeLuca NA: Expression of herpes simplex virus ICPO inhibits the induction of interferon-stimulated genes by viral infection. J Virol 2002;76:2180-2191.
72. Mossman KL, Macgregor PF, Rozmus JJ, Goryachev AB, Edwards AM, and Smiley JR: Herpes simplex virus triggers and then disarms a host antiviral response. J Virol 2001;75:750-758.
73. Nicholl MJ, Robinson LH, and Preston CM: Activation of cellular interferon-responsive genes after infection of human cells with herpes simplex virus type 1. J Gen Virol 2000;81:2215-2218.
74. Preston CM, Harman AN, and Nicholl MJ: Activation of interferon response factor-3 in human cells infected with herpes simplex virus type 1 or human cytomegalovirus. J Virol 2001;75:8909-8916.
75. Lin R, Noyce RS, Collins SE, Everett RD, and Mossman KL: The herpes simplex virus ICPO RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. J Virol 2004;78:1675-1684.
76. Melroe GT, DeLuca NA, and Knipe DM: Herpes simplex virus 1 has multiple mechanisms for blocking virus-induced interferon production. J Virol 2004;78:8411-8420.
77. Harle P, Sainz B Jr, Carr DJ, and Halford WP: The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-α/β. Virology 2002;293:295-304.
78. Mossman KL, Saffran HA, and Smiley JR: Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol 2000;74:2052-2056.
79. Mossman KL and Smiley JR: Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. J Virol 2002;76:1995-1998.
80. Leib DA, Harrison TE, Laslo KM, Machalek MA, Moorman NJ, and Virgin HW: Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J Exp Med 1999;189:663-672.
81. Chee AV, Lopez P, Pandolfi PP, and Roizman B: Promyelocytic leukemia protein mediates interferon-based antiherpes simplex virus 1 effects. J Virol 2003;77:7101-7105.
82. Salomoni P and Pandolfi PP: The role of PML in tumor suppression. Cell 2002;108:165-170.
83. Karpova AY, Trost M, Murray JM, Cantley LC, and Howley PM: Interferon regulatory factor-3 is an in vivo target of DNA-PK. Proc Natl Acad Sci USA 2002;99:2818-2823.
84. Sobol PT and Mossman KL: ICPO prevents RNase L-independent rRNA cleavage in herpes simplex virus type 1-infected cells. J Virol 2006;80:218-225.
85. Ali SH, Kasper JS, Arai T, and DeCaprio JA: Cu17/p185/p193 binding to simian virus 40 large T antigen has a role in cellular transformation. J Virol 2004;78:2749-2757.
86. Cathomen T and Weitzman MD: A functional complex of adenovirus proteins E1B-55kDa and E4orf6 is necessary to modulate the expression level of p53 but not its transcriptional activity. J Virol 2000;74:11407-11412.
87. Harada JN, Shevchenko A, Shevchenko A, Pallas DC, and Berk AJ: Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol 2002;76:9194-9206.
88. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, and Branton PE: Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 2001;15:3104-3117.
89. Querido E, Marcellus RC, Lai A, Charbonneau R, Teodoro JG, Ketner G, and Branton PE: Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells. J Virol 1997;71:3788-3798.
90. Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, and Branton PE: Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-ElB55K complex. J Virol 2001;75:699-709.
91. Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, and Bos JL: The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 1998;16:349-357.
92. Berk AJ: Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005;24:7673-7685.
93. Roth J and Dobbelstein M: Interaction of p53 with the adenovirus E1B-55 kDa protein. Methods Mol Biol 2003;234:135-149.
94. Blanchette P, Cheng CY, Yan Q, Keiner G, Ornelles DA. Dobner T, Conaway RC, Conaway JW, and Branton PE: Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53. Mol Cell Biol 2004;24:9619-9629.
95. Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Reac MA, and Kaelin WG Jr: An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammaliar cells. EMBO Rep 2002;3:177-182.
96. Stracker TH, Carson CT, and Weitzman MD: Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 2002;418:348-352.
97. Liu Y, Shevchenko A, Shevchenko A, and Berk AJ: Adenovirus exploits the cellular aggresome response to accelerate inactivation of the MRN complex. J Virol 2005;79:14004-14016.
98. Dobner T, Horikoshi N, Rubenwolf S, and Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 1996;272 1470-1473.
99. Martin ME and Berk AJ: Adenovirus E1B 55K represses p53 activation in vitro. J Virol 1998;72:3146-3154.
100. Liu Y, Colosimo AL, Yang XJ, and Liao D: Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol Cell Biol 2000;20:5540-5553.
101. Burgert HG, Ruzsics Z, Obermeier S, Hilgendorf A, Windheim M, and Elsing A: Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 2002;269:273-318.
102. Rose KM, Marin M, Kozak SL, and Rabat D: The viral infectivity factor (Vif) of HIV-1 unveiled. Trends Mol Med 2004;10:291-297.
103. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, and Yu XF: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003;302:1056-1060.
104. Yu Y, Xiao Z, Ehrlich ES, Yu X, and Yu XF: Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 2004;18:2867-2872.
105. Mehle A, Goncalves J, Santa-Marta M, McPike M, and Gabuzda D: Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 2004;18:2861-2866.
106. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, and Yu XF: Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci USA 2005;102:11444-11449.
107. Liu B, Sarkis PT, Luo K, Yu Y, and Yu XF: Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J Virol 2005;79:9579-9587.
108. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, and Uchiyama T: Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem 2005;280:18573-18578.
109. Fujita M, Akari H, Sakurai A, Yoshida A, Chiba T, Tanaka K, Strebel K, and Adachi A: Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect 2004;6:791-798.
110. Dussart S, Douaisi M, Courcoul M, Bessou G, Vigne R, and Decroly E: APOBEC3G ubiquitination by Nedd4-1 favors its packaging into HIV-1 particles. J Mol Biol 2005;345:547-558.
111. Santa-Marta M, da Silva FA, Fonseca AM, and Goncalves J: HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem 2005;280:8765-8775.
112. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, and Sheehy AM: Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 2005;15:166-170.
113. Tanaka Y, Marusawa H, Seno H, Matsumoto Y, Ueda Y, Kodama Y, Endo Y, Yamauchi J, Matsumoto T, Takaori-Kondo A, Ikai I, and Chiba T: Anti-viral protein APOBEC3G is induced by interferon-α stimulation in human hepatocytes. Biochem Biophys Res Commun 2006;341:314-319.
114. Li T, Chen X, Garbutt KC, Zhou P, and Zheng N: Structure of DDB1 in complex with a paramyxovirus V protein: Viral hijack of a propeller cluster in ubiquitin ligase. Cell 2006;124:105-117.
115. Lin GY, Paterson RG, Richardson CD, and Lamb RA: The V protein of the paramyxovirus SV5 interacts with damage-specific DNA binding protein. Virology 1998;249:189-200.
116. Ulane CM, Kentsis A, Cruz CD, Parisien JP, Schneider KL, and Horvath CM: Composition and assembly of STAT-targeting ubiquitin ligase complexes: Paramyxovirus V protein carboxyl terminus is an oligomerization domain. J Virol 2005;79:10180-10189.
117. Young DF, Chatziandreou N, He B, Goodbourn S, Lamb RA, and Randall RE: Single amino acid substitution in the V protein of simian virus 5 differentiates its ability to block interferon signaling in human and murine cells. J Virol 2001;75:3363-3370.
118. Precious B, Childs K, Fitzpatrick-Swallow V, Goodbourn S, and Randall RE: Simian virus 5 V protein acts as an adaptor, linking DDB1 to STAT2, to facilitate the ubiquitination of STAT1. J Virol 2005;79:13434-13441.
119. Andrejeva J, Young DF, Goodbourn S, and Randall RE: Degradation of STAT1 and STAT2 by the V proteins of simian virus 5 and human parainfluenza virus type 2, respectively: Consequences for virus replication in the presence of α/β and γ interferons. J Virol 2002;76:2159-2167.
120. Didcock L, Young DF, Goodbourn S, and Randall RE: The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J Virol 1999;73:9928-9933.
121. Ulane CM and Horvath CM: Paramyxoviruses SV5 and HPIV2 assemble STAT protein ubiquitin ligase complexes from cellular components. Virology 2002;304:160-166.
122. He B, Paterson RG, Stock N, Durbin JE, Durbin RK, Goodbourn S, Randall RE, and Lamb RA: Recovery of paramyxovirus simian virus 5 with a V protein lacking the conserved cysteine-rich domain: The multifunctional V protein blocks both interferon-β induction and interferon signaling. Virology 2002;303:15-32.
123. Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, and Randall RE: The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-β promoter. Proc Natl Acad Sci USA 2004;101:17264-17269.
124. Sun M, Rothermel TA, Shuman L, Aligo JA, Xu S, Lin Y, Lamb RA, and He B: Conserved cysteine-rich domain of paramyxovirus simian virus 5 V protein plays an important role in blocking apoptosis. J Virol 2004;78:5068-5078.
125. Lin Y, Horvath F, Aligo JA, Wilson R, and He B: The role of simian virus 5 V protein on viral RNA synthesis. Virology 2005;338:270-280.
126. Stephanou, A and Latchman DS: Opposing actions of STAT-1 and STAT-3. Growth Factors 2005;23:177-182.
127. Chen M, Cortay JC, Logan IR, Sapountzi V, Robson CN, and Gerlier D: Inhibition of ubiquitination and stabilization of human ubiquitin E3 ligase PIRH2 by measles virus phosphoprotein. J Virol 2005;79:11824-11836.
128. Nyman TA, Matikainen S, Sareneva T, Julkunen I, and Kalkkinen N: Proteome analysis reveals ubiquitin-conjugating enzymes to be a new family of interferon-α-regulated genes. Eur J Biochem 2000;267:4011-4019.
129. Okumura A, Lu G, Pitha-Rowe I, and Pitha PM: Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci USA 2006;103:1440-1445.
130. Yuan W and Krug RM: Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 2001;20:362-371.